Monarch Medical Technologies
Christophe Mallard is the Founder and General Partner of Eigen Capital LLC, a private investment firm established in September 2009. In addition, Christophe serves as a Board Member for Monarch Medical Technologies since September 2012, contributing to the advancement of the EndoTool product for insulin dosage management in critically ill patients. Previously, Christophe held the position of Chief Executive Officer at Plews and Edelmann from April 2011 to July 2016, where the company became a leader in North American lubrication equipment. Prior roles include Principal at H.I.G. Capital, Senior Vice President of Europe Acquisitions at Platinum Equity, Vice President at Deutsche Bank focusing on M&A and debt restructuring advisory, and various roles in investment banking at Deutsche Banc Alex. Brown, UBS Investment Bank, and Charterhouse Bank PLC. Christophe is an alumnus of HEC Paris, where studies took place from 1992 to 1994.
This person is not in the org chart
This person is not in any teams
Monarch Medical Technologies
Monarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. Insulin dosing has always been a daunting and time-intensive task, but now that burnout and staffing constraints have reached record highs, never have the associated risks and challenges been more acute. Add the impacts of new CMS measures for hyperglycemia and hypoglycemia, and you have the perfect storm. Our FDA-cleared EndoTool® Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with your EMR. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities, and has been shown to safely and reliably achieve and maintain target glucose goals. Specialized features help clinicians address the complexities of treating patients with diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, impaired kidney function, residual insulin, and presence of steroids.